Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 11 Study of Cilengitide in Combination With Concurrent Chemotherapy and Radiotherapy Followed by Protracted Daily Low Dose Temozolomide and Low Dose Procarbazine D1 - 20 in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Promoter Gene

NCT01124240 is registered in ClinicalTrials.gov with Northern Sydney and Central Coast Area Health Service as lead sponsor.

NCT NCT01124240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01124240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 11 Study of Cilengitide in Combination With Concurrent Chemotherapy and Radiotherapy Followed by Protracted Daily Low Dose Temozolomide and Low Dose Procarbazine D1 - 20 in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Promoter Gene
Lead sponsor
Northern Sydney and Central Coast Area Health Service
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2009
Completion date
January 31, 2014
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed non methylated glioblastoma multiforme grade 4